IL100128A - תכשירי רוקחות המכילים ברטאזניל לטיפול בהפרעות שינה - Google Patents
תכשירי רוקחות המכילים ברטאזניל לטיפול בהפרעות שינהInfo
- Publication number
- IL100128A IL100128A IL10012891A IL10012891A IL100128A IL 100128 A IL100128 A IL 100128A IL 10012891 A IL10012891 A IL 10012891A IL 10012891 A IL10012891 A IL 10012891A IL 100128 A IL100128 A IL 100128A
- Authority
- IL
- Israel
- Prior art keywords
- bretazenil
- sleep
- treatment
- sleep disorders
- pharmaceutical compositions
- Prior art date
Links
- 208000019116 sleep disease Diseases 0.000 title claims abstract description 11
- LWUDDYHYYNNIQI-ZDUSSCGKSA-N bretazenil Chemical compound O=C1C2=C(Br)C=CC=C2N2C=NC(C(=O)OC(C)(C)C)=C2[C@@H]2CCCN21 LWUDDYHYYNNIQI-ZDUSSCGKSA-N 0.000 title claims description 28
- 229950010832 bretazenil Drugs 0.000 title claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 title description 2
- 239000003814 drug Substances 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000012876 carrier material Substances 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- -1 compound t-butyl (S)-8-bromo-11,12,13,13a-tetrahydro-9-oxo-9H-imidazo[1,5-a]pyrrolo[2,1 -c][1,4]benzodiazepine-1-carboxylate Chemical class 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 2
- 230000007958 sleep Effects 0.000 description 19
- 239000000556 agonist Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 102000004300 GABA-A Receptors Human genes 0.000 description 9
- 108090000839 GABA-A Receptors Proteins 0.000 description 9
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 9
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 9
- 239000000126 substance Substances 0.000 description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- 239000001828 Gelatine Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 235000019759 Maize starch Nutrition 0.000 description 3
- 229940049706 benzodiazepine Drugs 0.000 description 3
- 150000001557 benzodiazepines Chemical class 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000008452 non REM sleep Effects 0.000 description 3
- 239000004031 partial agonist Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 230000004461 rapid eye movement Effects 0.000 description 3
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 2
- 230000002082 anti-convulsion Effects 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000008667 sleep stage Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 230000004620 sleep latency Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Anesthesiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH377690 | 1990-11-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL100128A0 IL100128A0 (en) | 1992-08-18 |
| IL100128A true IL100128A (he) | 1995-06-29 |
Family
ID=4263243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL10012891A IL100128A (he) | 1990-11-29 | 1991-11-22 | תכשירי רוקחות המכילים ברטאזניל לטיפול בהפרעות שינה |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5221672A (he) |
| EP (1) | EP0488044B1 (he) |
| JP (1) | JPH04266825A (he) |
| KR (1) | KR100193929B1 (he) |
| AT (1) | ATE134135T1 (he) |
| AU (1) | AU653966B2 (he) |
| CA (1) | CA2055308A1 (he) |
| DE (1) | DE59107405D1 (he) |
| DK (1) | DK0488044T3 (he) |
| ES (1) | ES2083503T3 (he) |
| GR (1) | GR3019327T3 (he) |
| HU (1) | HUT60624A (he) |
| IE (1) | IE72465B1 (he) |
| IL (1) | IL100128A (he) |
| MX (1) | MX9102181A (he) |
| ZA (1) | ZA919261B (he) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5317018A (en) * | 1992-06-09 | 1994-05-31 | Armin Walser | Benzodiazepines and compositions for treating anxiety and panic disorders, and idiopathic and psychomotor epilepsy |
| AU698834B2 (en) * | 1993-05-24 | 1998-11-12 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1185602A (en) * | 1981-02-27 | 1985-04-16 | Emilio Kyburz | Imidazodiazepines |
| CA1184175A (en) * | 1981-02-27 | 1985-03-19 | Walter Hunkeler | Imidazodiazepines |
| CA1327008C (en) * | 1988-01-15 | 1994-02-15 | Walter Merz | Anti-psychotic imidazobenzodiazepine |
| CA1312825C (en) * | 1988-01-27 | 1993-01-19 | F. Hoffmann-La Roche Ag | Prevention or interruption of panic states with an imidazobenzodiazepine |
| US4950664A (en) * | 1988-09-16 | 1990-08-21 | Rugby-Darby Group Companies, Inc. | Nasal administration of benzodiazepine hypnotics |
-
1991
- 1991-11-12 CA CA002055308A patent/CA2055308A1/en not_active Abandoned
- 1991-11-21 DK DK91119823.2T patent/DK0488044T3/da active
- 1991-11-21 ES ES91119823T patent/ES2083503T3/es not_active Expired - Lifetime
- 1991-11-21 DE DE59107405T patent/DE59107405D1/de not_active Expired - Fee Related
- 1991-11-21 EP EP91119823A patent/EP0488044B1/de not_active Expired - Lifetime
- 1991-11-21 AT AT91119823T patent/ATE134135T1/de not_active IP Right Cessation
- 1991-11-22 ZA ZA919261A patent/ZA919261B/xx unknown
- 1991-11-22 IL IL10012891A patent/IL100128A/he not_active IP Right Cessation
- 1991-11-22 MX MX9102181A patent/MX9102181A/es unknown
- 1991-11-25 AU AU88150/91A patent/AU653966B2/en not_active Ceased
- 1991-11-25 HU HU913660A patent/HUT60624A/hu unknown
- 1991-11-26 JP JP3335436A patent/JPH04266825A/ja active Pending
- 1991-11-27 US US07/800,791 patent/US5221672A/en not_active Expired - Fee Related
- 1991-11-27 KR KR1019910021373A patent/KR100193929B1/ko not_active Expired - Fee Related
- 1991-11-28 IE IE414891A patent/IE72465B1/en not_active IP Right Cessation
-
1996
- 1996-03-15 GR GR960400713T patent/GR3019327T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR100193929B1 (ko) | 1999-06-15 |
| KR920009403A (ko) | 1992-06-25 |
| IE914148A1 (en) | 1992-06-03 |
| US5221672A (en) | 1993-06-22 |
| CA2055308A1 (en) | 1992-05-30 |
| JPH04266825A (ja) | 1992-09-22 |
| DE59107405D1 (de) | 1996-03-28 |
| IE72465B1 (en) | 1997-04-09 |
| GR3019327T3 (en) | 1996-06-30 |
| ATE134135T1 (de) | 1996-02-15 |
| EP0488044B1 (de) | 1996-02-14 |
| AU653966B2 (en) | 1994-10-20 |
| HU913660D0 (en) | 1992-02-28 |
| ES2083503T3 (es) | 1996-04-16 |
| EP0488044A1 (de) | 1992-06-03 |
| DK0488044T3 (da) | 1996-03-11 |
| HUT60624A (en) | 1992-10-28 |
| MX9102181A (es) | 1992-07-08 |
| AU8815091A (en) | 1992-06-04 |
| IL100128A0 (en) | 1992-08-18 |
| ZA919261B (en) | 1992-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0840601B1 (en) | Thip for treating sleep disorders | |
| DE69910795T2 (de) | Pharmazeutische kombination mit einer trizyclischen verbindung und mindestens einer von zolpidem, zopiclone und brotizolam, zur behandlung oder verhinderung von schlafstörungen | |
| US6417184B1 (en) | Triple drug therapy for the treatment and prevention of acute or chronic pain | |
| US5786357A (en) | Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone | |
| US4634703A (en) | Method for alleviation of panic disorders | |
| Lust et al. | Cyclic nucleotides in murine brain: the temporal relationship of changes induced in adenosine 3′, 5′‐monophosphate and guanosine 3′, 5′‐monophosphate following maximal electroshock or decapitation | |
| ZA200608241B (en) | Use of peptidic compounds for the prophylaxis and treatment of chronic headache | |
| Tang et al. | Behavioral effects of U-78875, a quinoxalinone anxiolytic with potent benzodiazepine antagonist activity. | |
| CZ355897A3 (cs) | Způsob léčení mánie a bipolárních poruch | |
| Pangalila‐Ratu Langi et al. | Ritanserin in the treatment of generalized anxiety disorders: a placebo‐controlled trial | |
| CZ20033379A3 (cs) | Nová léčba obsedantně kompulzivních poruch (OCD) a OCD-příbuzných poruch s použitím GVB | |
| US5221672A (en) | Pharmaceutical compositions containing bretazenil and methods of using them | |
| WO1993010787A1 (en) | Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (+) zopiclone | |
| PL217743B1 (pl) | Zastosowanie inhibitorów ICE/kaspazy-1 do leczenia napadów i konwulsji w epilepsji oraz zawierające je kompozycja farmaceutyczna i zestaw | |
| DE60016803T2 (de) | Heilmittel und/oder prophylactische mittel zur behandlung von nervensystem-störungen | |
| JPH0623105B2 (ja) | てんかんの発作の治療用製薬組成物 | |
| AU701527B2 (en) | Method for treating anxiety | |
| CA2074039C (en) | Antihypertensive combination | |
| US4500524A (en) | Tranquilizing and reducing or preventing seizures | |
| NO317593B1 (no) | Fremgangsmate til a behandle pulmonal hypertensjon | |
| DE69923982T2 (de) | Verwendung einer zusammensetzung enthaltend eine assoziation eines angiotensin ii at1 rezeptor antagonists und indomethacin zur herstellung eines arzneimittels zur behandlung von kronischen glomerulonephriten | |
| Evans et al. | Chlormethiazole, sleep, and drug withdrawal | |
| EP1391203A1 (en) | Antitumor agents | |
| JPH01132520A (ja) | 高脂血症治療用組成物 | |
| WO2003029272A2 (en) | A method of treating schizophrenia and bipolar disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| RH | Patent void |